Uncategorized

  • CellAegis to complete enrollment in U.S. autoRIC trial by end of 2018

    May 8, 2018

    In addition to several large ongoing investigator-sponsored studies in Europe and Canada using its autoRIC device for automated remote ischemic conditioning (RIC), closely-held CellAegis Devices expects its own U.S. pivotal trial for the treatment of elective percutaneous coronary intervention (ePCI) to complete enrolment before the end of 2018. Link to Press Release

    Read More